“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

Frank A. Damelio net worth and biography

Frank Damelio Biography and Net Worth

EVP of Pfizer

Frank A. D'Amelio is on the board of Humana, Inc., Zoetis, Inc. (former Chairman), Independent College Fund of New Jersey and The Gillen Brewer School. In the past he occupied the position of Chief Financial Officer & EVP-Global Supply at Pfizer Inc., Principal at AT&T, Inc., Chief Operating Officer & Director at Lucent Technologies, Inc., Chief Administrative Officer & SEVP-Integration at Alcatel-Lucent SAS, Chief Administrative Officer & Senior Executive VP at Nokia of America Corp. and Principal at Bell Laboratories.

Mr. D'Amelio received an undergraduate degree from Saint Peter's University and an MBA from St. John's University.

What is Frank A. Damelio's net worth?: The estimated net worth of Frank A. Damelio is at least $12.37 million as of July 2nd, 2019. Mr. Damelio owns 489,647 shares of Pfizer stock worth more than $12,368,483 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Damelio may own. Learn More about Frank A. Damelio's net worth.
How do I contact Frank A. Damelio?: The corporate mailing address for Mr. Damelio and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Frank A. Damelio's contact information.
Has Frank A. Damelio been buying or selling shares of Pfizer?: Frank A. Damelio has not been actively trading shares of Pfizer over the course of the past ninety days. Most recently, Frank A. Damelio sold 153,184 shares of the business's stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a transaction totalling $6,753,882.56. Following the completion of the sale, the executive vice president now directly owns 489,647 shares of the company's stock, valued at $21,588,536.23. Learn More on Frank A. Damelio's trading history.
Who are Pfizer's active insiders?: Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.
Are insiders buying or selling shares of Pfizer?: In the last year, Pfizer insiders bought shares 3 times. They purchased a total of 5,000 shares worth more than $156,410.00. The most recent insider tranaction occured on December, 15th when Director Scott Gottlieb bought 3,000 shares worth more than $79,410.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.
Information on this page was last updated on 12/15/2023.

Frank A. Damelio Insider Trading History at Pfizer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2019	Sell	153,184	$44.09	$6,753,882.56	489,647
8/1/2018	Sell	150,484	$40.00	$6,019,360.00	337,391
8/31/2017	Sell	94,409	$34.00	$3,209,906.00	337,389
5/26/2016	Sell	100,000	$34.49	$3,449,000.00	472,994
5/10/2016	Sell	192,000	$33.66	$6,462,720.00	564,994
5/3/2016	Sell	87,079	$33.65	$2,930,208.35	372,994
2/11/2015	Sell	14,800	$34.30	$507,640.00

Frank A. Damelio Buying and Selling Activity at Pfizer

Pfizer Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Today's Range

Now: $25.26

$25.25

$26.43

50 Day Range

MA: $27.01

$25.26

$28.37

2 Week Range

Now: $25.26

$25.23

$40.37

Volume

47,041,425 shs

Average Volume

41,958,969 shs

Market Capitalization

$143.04 billion

P/E Ratio

70.17

Dividend Yield

6.38%

Beta

0.61